Note to users. If you're seeing this message, it means that your browser cannot find this page's style/presentation instructions -- or possibly that you are using a browser that does not support current Web standards. Find out more about why this message is appearing, and what you can do to make your experience of our site the best it can be.

Published Online June 21, 2001
Science DOI: 10.1126/science.1062876

Policy Forum

Submitted on May 25, 2001
Accepted on June 7, 2001

Resource Needs for HIV/AIDS

B. Schwartländer 1*, J. Stover 2, N. Walker 1, L. Bollinger 2, J. P. Gutierrez 3, W. McGreevey 2, M. Opuni 3, S. Forsythe 2, L. Kumaranayake 4, C. Watts 5, S. Bertozzi 3

1 Joint United Nations Programme on HIV/AIDS (UNAIDS), Geneva, Switzerland.
2 The Futures Group International, Washington, DC 20036, USA.
3 National Institute of Public Health, Cuernavaca, Mexico.
4 Department of Public Health and Policy, London School of Hygiene and Tropical Medicine, London, UK.
5 Department of Public Health and Policy, London School of Hygiene and Tropical Medicine, London, UK.

* To whom correspondence should be addressed. E-mail: schwartlanderb{at}unaids.org.

Government and civil society representatives meet for a Special Session of the General Assembly of the United Nations (UNGASS) 25 to 27 June 2001 to consider an expanded response to HIV/AIDS. This policy forum estimates that by 2005, that response will require about US$9 billion annually, with half of these resources needed in sub-Saharan Africa. About US$4.8 billion is required for prevention including interventions focusing on youth, workplace programs, mother-to-child transmission and condom distribution. US$4.4 billion is needed for palliative care, treatment and prophylaxis of opportunistic infections, support for orphans, and antiretroviral therapy. One-third to one-half of these resources can come from domestic sources, both public and private, with the remainder needed from international sources.


THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES:
Critical Choices In Financing The Response To The Global HIV/AIDS Pandemic.
R. Hecht, L. Bollinger, J. Stover, W. McGreevey, F. Muhib, C. E. Madavo, and D. de Ferranti (2009)
Health Aff. 28, 1591-1605
   Abstract »    Full Text »    PDF »
Improved Survival in Rhesus Macaques Immunized with Modified Vaccinia Virus Ankara Recombinants Expressing Simian Immunodeficiency Virus Envelope Correlates with Reduction in Memory CD4+ T-Cell Loss and Higher Titers of Neutralizing Antibody.
I. Ourmanov, T. Kuwata, R. Goeken, S. Goldstein, R. Iyengar, A. Buckler-White, B. Lafont, and V. M. Hirsch (2009)
J. Virol. 83, 5388-5400
   Abstract »    Full Text »    PDF »
Correlation of Vaccine-Elicited Systemic and Mucosal Nonneutralizing Antibody Activities with Reduced Acute Viremia following Intrarectal Simian Immunodeficiency Virus SIVmac251 Challenge of Rhesus Macaques.
R. Hidajat, P. Xiao, Q. Zhou, D. Venzon, L. E. Summers, V. S. Kalyanaraman, D. C. Montefiori, and M. Robert-Guroff (2009)
J. Virol. 83, 791-801
   Abstract »    Full Text »    PDF »
Saving newborn lives in Asia and Africa: cost and impact of phased scale-up of interventions within the continuum of care.
G. L Darmstadt, N. Walker, J. E Lawn, Z. A Bhutta, R. A Haws, and S. Cousens (2008)
Health Policy Plan. 23, 101-117
   Abstract »    Full Text »    PDF »
An HIV-1 clade C DNA prime, NYVAC boost vaccine regimen induces reliable, polyfunctional, and long-lasting T cell responses.
A. Harari, P.-A. Bart, W. Stohr, G. Tapia, M. Garcia, E. Medjitna-Rais, S. Burnet, C. Cellerai, O. Erlwein, T. Barber, et al. (2008)
J. Exp. Med. 205, 63-77
   Abstract »    Full Text »    PDF »
The Magnitude of Key HIV Prevention Challenges in the United States: Implications for a New National HIV Prevention Plan.
D. R. Holtgrave, J. F. McGuire, and J. Milan Jr (2007)
Am J Public Health 97, 1163-1167
   Abstract »    Full Text »    PDF »
Scaling up priority health interventions in Tanzania: the human resources challenge.
C. Kurowski, K. Wyss, S. Abdulla, and A. Mills (2007)
Health Policy Plan. 22, 113-127
   Abstract »    Full Text »    PDF »
Cost-Effectiveness of HIV Treatment in Resource-Poor Settings -- The Case of Cote d'Ivoire.
S. J. Goldie, Y. Yazdanpanah, E. Losina, M. C. Weinstein, X. Anglaret, R. P. Walensky, H. E. Hsu, A. Kimmel, C. Holmes, J. E. Kaplan, et al. (2006)
N. Engl. J. Med. 355, 1141-1153
   Abstract »    Full Text »    PDF »
The Global Impact of Scaling Up HIV/AIDS Prevention Programs in Low- and Middle-Income Countries.
J. Stover, S. Bertozzi, J.-P. Gutierrez, N. Walker, K. A. Stanecki, R. Greener, E. Gouws, C. Hankins, G. P. Garnett, J. A. Salomon, et al. (2006)
Science 311, 1474-1476
   Abstract »    Full Text »    PDF »
Cost effectiveness analysis of strategies to combat HIV/AIDS in developing countries.
D. R Hogan, R. Baltussen, C. Hayashi, J. A Lauer, and J. A Salomon (2005)
BMJ 331, 1431-1437
   Abstract »    Full Text »    PDF »
Population-Level HIV Declines and Behavioral Risk Avoidance in Uganda.
R. L. Stoneburner and D. Low-Beer (2004)
Science 304, 714-718
   Abstract »    Full Text »    PDF »
Ethics and the AIDS Pandemic in the Developing World.
M. J. Ahn, A. Grimwood, H. Schwarzwald, and A. Herman (2003)
J Int Assoc Physicians AIDS Care (Chic Ill) 2, 81-87
   Abstract »    PDF »
Societal Change to Prevent Obesity.
S. P. Weisberg (2002)
JAMA 288, 2176
   Full Text »    PDF »
An Unequal Epidemic in an Unequal World.
K. M. De Cock and R. S. Janssen (2002)
JAMA 288, 236-238
   Full Text »    PDF »
Structured intermittent treatment for HIV disease: Necessary concession or premature compromise?.
D. V. Havlir (2002)
PNAS 99, 4-6
   Full Text »    PDF »
Introduction.
P. Piot (2001)
Br. Med. Bull. 58, 3-5
   Full Text »    PDF »


To Advertise     Find Products

Science. ISSN 0036-8075 (print), 1095-9203 (online)